AR095691A1 - FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO - Google Patents

FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO

Info

Publication number
AR095691A1
AR095691A1 ARP140101303A ARP140101303A AR095691A1 AR 095691 A1 AR095691 A1 AR 095691A1 AR P140101303 A ARP140101303 A AR P140101303A AR P140101303 A ARP140101303 A AR P140101303A AR 095691 A1 AR095691 A1 AR 095691A1
Authority
AR
Argentina
Prior art keywords
methylethydropholate
amorfo
mthf
formulation
procedure
Prior art date
Application number
ARP140101303A
Other languages
English (en)
Inventor
Diaz Del Consuelo Isabel
Hernandez Herrero Gonzalo
Ronchi Celestino
Original Assignee
Chemo Res S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48045387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR095691(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemo Res S L filed Critical Chemo Res S L
Publication of AR095691A1 publication Critical patent/AR095691A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Forma farmacéutica que comprende L-5-metilfolato de calcio amorfo y cisteína como agente estabilizante y opcionalmente, agentes auxiliares adicionales. Reivindicación 5: Forma farmacéutica según una cualquiera de las reivindicaciones 1 a 3, que comprende además: de 10 a 50 mg de etinil estradiol, de 0,5 a 5 mg de drospirenona.
ARP140101303A 2013-03-22 2014-03-20 FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO AR095691A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382106.6A EP2781214A1 (en) 2013-03-22 2013-03-22 Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)

Publications (1)

Publication Number Publication Date
AR095691A1 true AR095691A1 (es) 2015-11-04

Family

ID=48045387

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101303A AR095691A1 (es) 2013-03-22 2014-03-20 FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO

Country Status (10)

Country Link
US (1) US20160045440A1 (es)
EP (2) EP2781214A1 (es)
AR (1) AR095691A1 (es)
BR (1) BR112015024351A2 (es)
CA (1) CA2907746A1 (es)
CL (1) CL2015002817A1 (es)
MX (1) MX2015013535A (es)
PE (1) PE20151891A1 (es)
RU (1) RU2015139983A (es)
WO (1) WO2014146975A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3190112A4 (en) * 2014-09-04 2017-09-13 Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. Composition of (6s)-5-methyl tetrahydrofolic acid or salt thereof as well as preparation therefor and application thereof
WO2016123076A1 (en) * 2015-01-27 2016-08-04 La Vita Compounding Pharmacy Stable 5-methyltrahydrofolate formulations to moderate methylenetetrahydrofolate reductase associated polymorphisms
CA3036511A1 (en) * 2016-09-12 2018-03-15 Steven Hoffman Compositions for treating dementia
CN109164182B (zh) * 2018-09-19 2021-06-11 无锡紫杉药业有限公司 一种对l-四氢叶酸对甲苯磺酸盐（6s）光学纯度的分析检测方法
EP3666260A1 (en) 2018-12-13 2020-06-17 Laboratorios Leon Farma SA Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof
IL298209A (en) 2020-05-15 2023-01-01 Alfasigma Spa A preparation containing methylfolate
CN113403355B (zh) * 2021-06-17 2022-05-31 山东大学 一种生物法生产l-5-甲基四氢叶酸的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223500A (en) * 1977-02-22 1993-06-29 Bioresearch S.P.A. Stable pharmaceutical composition of alkaline or alkaline earth 5-methyl tetrahydrofolate
US5124452A (en) * 1978-07-10 1992-06-23 Bioresearch S.P.A. Process for producing d,1-5-methyltetrahydrofolic acid and its salts
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
CH698729B1 (de) 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
CN102813656B (zh) * 2012-09-13 2014-05-07 广东岭南制药有限公司 5-甲基四氢叶酸或其盐的稳定药物组合物

Also Published As

Publication number Publication date
US20160045440A1 (en) 2016-02-18
CL2015002817A1 (es) 2016-03-11
BR112015024351A2 (pt) 2017-07-18
MX2015013535A (es) 2016-05-31
RU2015139983A (ru) 2017-04-25
CA2907746A1 (en) 2014-09-25
PE20151891A1 (es) 2015-12-20
EP2781214A1 (en) 2014-09-24
EP2976066A1 (en) 2016-01-27
WO2014146975A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
AR095691A1 (es) FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
CL2017002792A1 (es) Derivados de ciclohexano sustituido con amido
CL2016001547A1 (es) Composiciones para el cuidado oral
PE20151778A1 (es) Formulacion combinada de dos compuestos antivirales
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
BR112017028048A2 (pt) drospirenona como o único ingrediente contraceptivo para uso
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CL2015002433A1 (es) Imidazopiridazinas sustituidas
DOP2016000007A (es) Pirazolpiridinas sustituidas
UY35848A (es) Tienopirimidinas
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2017003437A1 (es) Formulación solida oral que contiene irinotecán y método de preparación de la misma
CO2017006958A2 (es) Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para la preparación y uso de los mismos
CL2015001748A1 (es) Formulaciones antiparasitarias transdermicas
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
MX2016005092A (es) Composiciones farmaceuticas de estradiol insertadas en la vagina y metodos.
CL2019000174A1 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d.
UY37444A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
CL2015003014A1 (es) Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas.
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
EP2987492A4 (en) USE OF 7A- [9- (4,4,5,5,5-PENTAFLUOR-PENTYL-SULFINYL-) NONYL] ESTRA-1,3,5 (10) -TRIEN-3,17B-DIOL AND DERIVATIVES THEREOF
CO7131364A2 (es) Anillo vaginal que comprende meloxicam y un agente modulador de la liberación del principio activo, útil como anticonceptivo de uso continuo en mujeres

Legal Events

Date Code Title Description
FB Suspension of granting procedure